Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. by Shi, Hubing et al.
UCLA
UCLA Previously Published Works
Title
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated 
acquired B-RAF inhibitor resistance.
Permalink
https://escholarship.org/uc/item/395079ws
Journal
Nature communications, 3(1)
ISSN
2041-1723
Authors
Shi, Hubing
Moriceau, Gatien
Kong, Xiangju
et al.
Publication Date
2012-03-06
DOI
10.1038/ncomms1727
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Melanoma whole exome sequencing identifies V600EB-RAF 
amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi1,8, Gatien Moriceau1,8,*, Xiangju Kong1,8,*, Mi-Kyung Lee1,8,*, Hane Lee2,3,8, 
Richard C. Koya4,8, Charles Ng5,8, Thinle Chodon5,8, Richard A. Scolyer9,10,12, Kimberly B. 
Dahlman13,15, Jeffrey A. Sosman14,15, Richard F. Kefford9,11,12, Georgina V. Long9,11,12, 
Stanley F. Nelson2,3,7,8, Antoni Ribas4,5,6,7,8, and Roger S. Lo1,6,7,8
1Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University 
of California, LA, California 90095-1662 USA
2Department of Human Genetics, David Geffen School of Medicine, University of California, LA, 
California 90095-1662 USA
3Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University 
of California, LA, California 90095-1662 USA
4Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, 
University of California, LA, California 90095-1662 USA
5Division of Hematology & Oncology, Department of Medicine, David Geffen School of Medicine, 
University of California, LA, California 90095-1662 USA
6Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, 
University of California, LA, California 90095-1662 USA
7Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of 
California, LA, California 90095-1662 USA
8David Geffen School of Medicine, University of California, LA, California 90095-1662 USA
9Melanoma Institute of Australia, University of Sidney, New South Wales, Australia
10Royal Prince Alfred Hospital, University of Sidney, New South Wales, Australia
11Westmead Millenium Institute, University of Sidney, New South Wales, Australia
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
Address for correspondence: Dr. Roger S. Lo at 52-121 CHS Dept. of Medicine/Dermatology, 10833 Le Conte Ave, Los Angeles, CA 
90095-1750 or at rlo@mednet.ucla.edu.
*These authors contributed equally to this work
Author Contributions H.S., G.M., X.K., M-K.L., H.L. designed, performed experiments and analyzed data. R.C.K., C.N., T.C. 
R.A.S., K.D., J.A.S., R.F.K., G.V.L., A.R., and R.S.L. recruited patient volunteers and/or provided reagents/tissues. H.S., G.M., X.K, 
M-K.L., H.L., J.A.S., R.F.K., G.V.L., S.F.N. and A.R. contributed to manuscript preparation. R.S.L. designed experiments and 
research aims, analyzed data, and wrote the paper.
Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications.
Accession codes: Sequence data are archived at the NCBI Sequence Read Archive (SRA) under the accession code SRP010266.
Competing financial interests: A.R. and R.S.L. are the authors of patent application under PCT Application Serial No. PCT/
US11/061552 (Compositions and methods for detection and treatment of B-RAF inhibitor-resistant melanomas)
HHS Public Access
Author manuscript
Nat Commun. Author manuscript; available in PMC 2012 December 26.
Published in final edited form as:
Nat Commun. ; 3: 724. doi:10.1038/ncomms1727.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
12University of Sidney, New South Wales, Australia
13Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232
14Department of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TN 37232
15Vanderbilt-Ingram Cancer Center, Nashville, TN 37232
Abstract
The development of acquired drug resistance hampers the long-term success of B-RAF inhibitor 
(B-RAFi) therapy for melanoma patients. Here we show V600EB-RAF copy number gain as a 
mechanism of acquired B-RAFi resistance in four out of twenty (20%) patients treated with B-
RAFi. In cell lines, V600EB-RAF over-expression and knockdown conferred B-RAFi resistance 
and sensitivity, respectively. In V600EB-RAF amplification-driven (vs. mutant N-RAS-driven) B-
RAFi resistance, ERK reactivation is saturable, with higher doses of vemurafenib down-regulating 
pERK and re-sensitizing melanoma cells to B-RAFi. These two mechanisms of ERK reactivation 
are sensitive to the MEK1/2 inhibitor AZD6244/selumetinib or its combination with the B-RAFi 
vemurafenib. In contrast to mutant N-RAS-mediated V600EB-RAF bypass, which is sensitive to C-
RAF knockdown, V600EB-RAF amplification-mediated resistance functions largely independently 
of C-RAF. Thus, alternative clinical strategies may potentially overcome distinct modes of ERK 
reactivation underlying acquired B-RAFi resistance in melanoma.
Introduction
Activating B-RAF V600 kinase mutations occur in ~50% of melanomas1, and the ATP-
competitive type I RAF inhibitors, PLX4032/vemurafenib and GSK2118436, display 
remarkable activity leading to overall survival advantage in patients with V600B-RAF mutant 
melanomas2–6. Acquisition of drug resistance leading to clinical relapse, however, develops 
in virtually all patients treated with B-RAF inhibitors (B-RAFi)4,5. Heterogeneous 
mechanisms of acquired B-RAFi resistance hitherto uncovered fall into general MAPK-
redundant, AKT-dependent7,8 or MAPK-reactivating9,10 pathways, indicating specific 
translatable therapeutic strategies to prevent or overcome resistance. Contrary to 
expectation, V600EB-RAF secondary mutations have not been found to account for acquired 
B-RAFi resistance10, suggesting V600EB-RAF-bypass mechanisms as the principal means to 
ERK reactivation.
Here we observed an alteration in V600EB-RAF, namely genomic copy number gain, in 
tumors of melanoma patients whose cancer progressed after initial responses to B-RAF 
inhibitors. We demonstrated that this V600EB-RAF amplification results in V600EB-RAF 
over-expression, which is necessary and sufficient for acquired resistance to B-RAF 
inhibitor. This finding, along with a recent study reporting N-terminal truncation of V600EB-
RAF causing acquired B-RAFi resistance in melanoma11, underscores key molecular 
alterations in the drug target itself. We further suggest that V600EB-RAF-instrinsic 
(amplification, truncation) vs. V600EB-RAF-bypass (N-RAS mutations) mechanisms, both 
reactivating the MAPK pathway, may offer insights into distinct therapeutic strategies to 
overcome acquired B-RAFi resistance in melanoma.
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Results
Whole exome sequencing identifies V600EB-RAF amplification
We assembled twenty sets of patient-matched baseline (prior to B-RAFi therapy) and 
disease progression (DP) (i.e., acquired B-RAFi resistance) melanoma tissues and analyzed 
them to identify the proposed mechanisms of acquired B-RAFi resistance in melanoma. 
These reported mechanisms include N-RAS10 and MEK112 mutations, alternative-
spliced V600EB-RAF variants11, and over-expression of RTKs (PDGFRβ7,10, IGF1-R8) and 
COT9 (Tables 1 and Supplementary Table S1; Supplementary Fig. S1). For DP samples 
negative for these mechanisms and where there was sufficient frozen and patient-matched 
normal tissues (from patients #4, 5, 8, 14, 16, 17 & 18), we subjected triads of genomic 
DNAs (gDNAs) from normal, baseline, and DP tissues to whole exome sequencing. In two 
available data sets, we searched for somatic DP-specific non-synonymous single nucleotide 
variants (nsSNVs) and small insertion-deletion (indels), which were exceedingly few in 
number or absent, respectively, using our bioinformatic workflow (Supplementary Tables 
S2 and S3). We also analyzed for DP-specific copy number variations (CNVs) from the 
exome sequence data (Supplementary Table S2). This identified V600EB-RAF copy number 
gains in these two patients’ DP tissues (2.2 and 12.8 fold in patients #5 and 8, respectively) 
relative to their respective baseline tissues (Fig. 1a; Table 1). Gain in V600EB-RAF copy 
number was reflected in corresponding increased gene expression at the protein level (Fig. 
1b).
V600EB-RAF amplification was validated by gDNA Q-PCR, producing consistent fold 
increases in DP-specific V600EB-RAF copy number gain (relative to baseline) (2.0 and 14 
fold increase in patient #5 and 8 respectively) (Fig. 1c). We then expanded the analysis 
of V600EB-RAF amplification to all twenty paired melanoma tissues and detected V600EB-
RAF copy number gains in DP samples from two additional patients (2.3 and 3 fold for DP2 
of patient #9 & DP of patient #13, respectively) (Fig. 1c; Table 1). We note that these copy 
number fold increases are likely underestimates of the true changes due to non-tumor diploid 
cell contents and tumor heterogeneity, as most disease progressive tumors occur from stable 
residual tumors as a result of partial responses seen in the vast majority of patients treated 
with B-RAF inhibitors. An increase in the mutant B-RAF to WT B-RAF ratio was also noted 
in all four cases of DP harboring B-RAF copy number gain when compared to their 
respective baseline tissues (Fig. 1d), consistent with selection for V600EB-RAF (vs. the WT 
B-RAF allele) copy number gain during acquisition of B-RAFi resistance. V600EB-RAF 
amplification was largely mutually exclusive with N-RAS mutations (no enrichment in 
MEK1 exon 3 mutation was detected in DP vs. baseline tumors), RTK over-expression (no 
COT over-expression detected), as well as a novel mechanism involving V600EB-RAF 
alternative splicing11 (Table 1; Supplementary Fig. S1).
B-RAFi selects for V600EB-RAF gain and over-expression
We have derived vemurafenib/PLX4032-resistant (R) sub-lines by providing continuous 
vemurafenib exposure to seven human melanoma-derived V600EBRAF-positive parental (P) 
cell lines sensitive to vemurafenib-mediated growth inhibition. Four resistant sub-lines, 
including M229 R5 and M238 R17,10, over-expressed PDGFRβ compared to their parental 
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counterpart. One sub-line (M249 R410) gained a mutation in N-RAS, and another (M397 R) 
an alternatively spliced variant of V600EB-RAF resulting in in-frame fusion of exons 1 and 11 
(Supplementary Fig. S2). As in our tissue analysis, these mechanisms were identified in a 
mutually exclusive manner. Another vemurafenib-resistant sub-line, M395 R, was derived 
from a V600EB-RAF-homozygous parental line, M395 P (Supplementary Fig. S3a). 
Compared to M395 P, M395 R harbors increased copy numbers of V600EB-RAF gDNA and 
cDNA, consistent with a dramatic V600EB-RAF protein over-expression (Supplementary 
Fig. S3b, c, and d). M395 R displays growth highly resistant to vemurafenib treatment 
(Supplementary Fig. S4a), and titration of M395 R with vemurafenib (1 h) after a 24 h of 
drug withdrawal revealed pERK levels to be highly resistant to acute V600EB-RAF inhibition 
(Supplementary Fig. S4b). This pattern of MAPK reactivation was similar to that seen in a 
mutant N-RAS-driven, vemurafenib-resistant sub-line, M249 R4, and contrasted with that in 
the RTK-driven vemurafenib-resistant sub-line, M229 R5 (Supplementary Fig. S4b)7,10. 
Expectedly, the levels of p-AKT are unchanged (Fig. 2b) comparing M395 P vs. M395 R, 
consistent with a lack of RTK over-expression leading to MAPK-redundant, PI3K-AKT 
signaling7. Accordingly, M395 R does not over-express either PDGFRβ or IGF-1R, in 
contrast to M229 R5, which has been shown to over-express the RTK PDGFRβ 
(Supplementary Fig. S4c)7,8. Additionally, M395 R is WT for N-, H- and K-RAS and 
MEK1, harbors no secondary mutations in V600EB-RAF or an alternatively spliced variant 
of V600EB-RAF which results in a N-terminally truncated V600EB-RAF protein.
Modest V600EB-RAF over-expression leads to B-RAFi resistance
Three different but uniformly modest levels of V600EB-RAF over-expression were achieved 
by infecting M395 P with varying viral titers and subsequent puromycin selection. This 
resulted in relatively low (1.9 fold over empty vector virus control), medium (2.4 fold) and 
high (2.8 fold) levels of V600EB-RAF RNA/cDNA over-expression (Supplementary Fig. S5), 
with the corresponding protein over-expression levels shown in Figure 2a. In comparison, in 
two sets of tissues (from patients #8 and #13) where flash-frozen tissues were available, the 
RNA/cDNA levels of V600EB-RAF in the DP tumors were 9.5 and 1.4 fold relative to those 
in their patient-matched baseline tumors. Notably, the DP tumor from patient #13 was 
obtained by an intervention radiology-guided needle biopsy of a pelvic mass 
(Supplementary Table S1) and contained a high admixture of normal and tumor contents 
(latter indicated by S100), which likely contributed to an underestimation of the true change 
in the V600EB-RAF RNA/cDNA levels.
V600EB-RAF gain leads to drug-saturable resistance
The modest and incremental over-expression of V600EB-RAF at the RNA and protein levels 
in M395 P conferred similar degrees of vemurafenib resistance (Fig. 2b). Interestingly, 
further V600EB-RAF over-expression at a much greater level, as in the case of M395 R 
relative to M395 P (increase in RNA/cDNA level shown in Supplementary Fig. S3c and S5; 
increase in protein level shown in Fig. 2c) conferred enhanced drug resistance mainly at 1 
μM vemurafenib but not 10 μM vemurafenib (Fig. 2d). Thus, a modest V600EB-RAF copy 
number gain and over-expression can confer vemurafenib resistance, and even high 
amplitude V600EB-RAF amplification and over-expression can be readily saturable by 
micromolar concentrations of vemurafenib.
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Moreover, V600EB-RAF knockdown in M395 R confers vemurafenib sensitivity (Fig. 2c and 
d). Consistently, V600EB-RAF over-expression in M395 P (at a level titrated to be 
comparable to M395 R) and its knockdown in M395 R resulted in pERK resistance and 
sensitivity, respectively, to acute vemurafenib treatment after a 24 h drug withdrawal (Fig. 
2e). We predicted that, regardless of the cellular genetic context, MAPK reactivation due to 
drug target (i.e., V600EB-RAF) over-expression would be saturable by higher doses of 
vemurafenib, in contrast to mutant N-RAS-mediated MAPK reactivation where V600EB-
RAF may be bypassed by the alternative use of C-RAF13. Indeed, dosing of vemurafenib 
from 1 to 50 μM revealed a significant difference in drug sensitivity of M249 R4 (Q61KN-
RAS) vs. M395 R (amplified V600EB-RAF) (Fig. 3a) (where the latter was highly sensitive to 
vemurafenib at this drug concentration range), suggesting a potential therapeutic 
opportunity. To rule out that these results were not due to a difference in genetic 
backgrounds, we artificially rendered the V600EB-RAF melanoma cell line, M229, 
vemurafenib-resistant by either Q61KN-RAS or V600EB-RAF viral transduction (Fig. 3b). 
Again, high dose vemurafenib treatment was more effective at overcoming drug resistance 
in V600EB-RAF-transduced M229 than in the same cell line transduced with Q61KN-RAS.
MEK inhibition restores vemurafenib sensitivity
Since both N-RAS mutation and V600EB-RAF amplification-driven acquired resistance 
mechanisms would be anticipated to result in MEK reactivation, we tested the allosteric 
MEKi, AZD6244/selumetinib, on the Q61KN-RAS-driven M249 R4 and the V600EB-RAF 
amplification-driven M395 R sub-lines. MEKi treatment resulted in decreased proliferation 
in both cases, but the activity was noted at lower concentrations for the Q61KN-RAS-driven 
resistance mechanism (Fig. 3c). This differential pattern was reproducible by exposing 
AZD6244/selumetinib to V600EB-RAF melanoma cell lines M229 and M238 transduced with 
high levels of V600EB-RAF vs. a short-term culture, Pt55 R10, with Q61KN-RAS-driven 
acquired B-RAFi resistance (Fig. 3d). We also tested the combination of B-RAFi with 
MEKi, which is currently in clinical testing14, in three-day survival assays. A calculation of 
combination index (CI) values using equal ratios of vemurafenib and selumetinib was 
performed. The results were consistent with a highly synergistic effect of these two agents 
combined in overcoming both mutant N-RAS-driven (M249 R4) and V600EB-RAF 
amplification-driven B-RAFi resistance (M395 R) (Fig 3e and 3f), although the combination 
tended to be more potent against mutant N-RAS-driven acquired resistance to vemurafenib. 
This B-RAFi and MEKi combinatorial synergy was further corroborated in longer-term 
clonogenic assays (Fig. 3g).
Differential C-RAF dependency of ERK-reactivating mechanisms
We also predicted that MAPK reactivation due to V600EB-RAF over-expression would be C-
RAF-independent, in contrast to mutant N-RAS-mediated MAPK reactivation 
where V600EB-RAF may be bypassed by the alternative use of C-RAF. Indeed, C-RAF 
knockdown by shRNA sensitized the mutant N-RAS sub-line, M249 R4, but not the V600EB-
RAF amplified sub-line, M395 R, to vemurafenib in three-day survival assays (Fig. 3h). C-
RAF knockdown restored vemurafenib sensitivity to M249 R4 (Q61KN-RAS/V600EB-RAF) 
even more strikingly in a longer-term clonogenic assays which afforded fresh drug 
replacement every two days (Fig. 3i). An independent C-RAF shRNA also restored 
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vemurafenib sensitivity to M249 R4 (Supplementary Table S4). Additionally, B-RAFi and 
MEKi synergy and C-RAF-dependence in mutant N-RAS-driven acquired B-RAFi 
resistance was confirmed in a short-term culture derived from a tumor with clinical acquired 
vemurafenib resistance (Supplementary Fig. S6).
Discussion
Identification of V600EB-RAF amplification as a mechanism of acquired resistance in B-
RAFi treated patients provides evidence for alterations in the drug target causing clinical 
relapse. Based on these studies, therapeutic stratification of MAPK reactivation underlying 
B-RAFi resistance into drug-saturable or C-RAF-dependent pathways may be translatable 
into the design of next-generation clinical trials aimed at preventing or overcoming B-RAFi 
resistance (Fig. 4). These findings also provide pre-clinical rationale for dose escalation 
studies in selected patients with B-RAFi-resistant V600E/KB-RAF metastatic melanomas, 
particularly given the wide range of effective dosing and the fact that the maximum tolerated 
dose of GSK2118436 has not been determined. The combination of current B-RAF 
inhibitors (or next-generation RAF inhibitors that enhance B-RAF potency or feature pan-
RAF inhibition) with MEK1/2 inhibitors may potentially broadly block MAPK reactivation.
Emerging evidence points to B-RAF mutant cancers of other tissue origin or lineage being 
less responsive to specific B-RAF inhibition than B-RAF mutant melanomas. Mechanisms 
of acquired B-RAF inhibitor resistance may turn out to be instructive for understanding 
primary resistance of B-RAF mutant cancer types to B-RAF inhibitors, as primary (de novo) 
and secondary (or acquired) drug resistance may be clinical manifestations from a spectrum 
of molecular alterations that are mechanistically linked. Thus, multiple modes (e.g., 
mutation, copy number gain) of up-regulating oncogene activity, which may pre-exist in the 
same tumor and/or patient, may help explain the range of heterogeneous responses of B-RAF 
mutant cancers to direct B-RAF, MEK or ERK inhibition.
Methods
Cell culture experiments
Cells were maintained in DMEM with 10 or 20% fetal bovine serum and glutamine. 
shRNAs (Supplementary Table S4) for B-RAF and C-RAF were sub-cloned into the 
lentiviral vector pLL3.7; pBabe B-RAF (V600E) was purchase (plasmid 17544, Addgene); 
viral supernatants generated by co-transfection with three packaging plasmids into 
HEK293T cells; and infections carried out with protamine sulfate. Stocks and dilutions of 
PLX4032 (Plexxikon, Berkeley, CA) and AZD6244 (commercially available) were made in 
DMSO. Cells were quantified using CellTiter-GLO Luminescence (Promega) or crystal 
violet staining followed by NIH Image J quantification.
Whole exome sequencing
Human tissues were obtained with patient-informed consent under UCLA Institutional 
Review Board (#10-001089) approval. For each sample, 3ug of high molecular weight 
genomic DNA was used as the starting material to generate the sequencing library. Exome 
captures were performed using Agilent SureSelect Human All Exon 50mb and Agilent 
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SureSelect Human All Exon 50mb XT for PT #5 and Pt #8, respectively, per manufacturers’ 
recommendation, to create a mean 200bp insert library. For Pt #5, sequencing was 
performed on Illumina GenomeAnalyzerII (GAII) as 76+76bp paired-end run. The normal 
sample was run on 1 flowcell lane and the tumor samples were run on 2 flowcell lanes each. 
For Pt #8, sequencing was performed on Illumina HiSeq2000 as 50+50bp paired-end run 
and 100+100bp paired-end run. The three samples (normal, baseline and DP) were initially 
mixed with 9 other samples and run across 5 flowcell lanes for the 50+50bp run. For the 
100+100bp run, they were mixed with 3 other samples to be run across 5 flowcell lanes with 
barcoding of each individual genomic sample library.
For Pt #5, approximately 62 million, 137 million, 147 million reads were generated for 
normal tissue (skin), baseline melanoma and DP melanoma, respectively, with 75.2%, 
78.1%, and 74.7% of the reads mapping to capture targets. Based on an analysis of reads 
that uniquely aligned to the reference genome and for which the potential PCR duplicates 
were removed, an average coverage of 52X, 88X, and 114X was achieved with 87%, 92% 
and 93% of the targeted bases being covered at 10X or greater read depth for normal, 
baseline and DP, respectively.
For Pt #8, approximately 198 million, 270 million, 256 million reads were generated for 
normal tissue (skin), baseline melanoma and DP melanoma, respectively with 43.2%, 44.1% 
and 42.3% of the reads mapping to capture targets. Based on an analysis of reads that 
uniquely aligned to the reference genome and for which the potential PCR duplicates were 
removed, an average read depth of 107X, 132X and 123X was achieved with 89%, 90% and 
90% of the targeted bases being covered at 10X or greater for normal, baseline and DP, 
respectively.
Sequencing data analysis
For Pt #8 where the samples were indexed and pooled before the sequencing, Novobarcode 
from Novocraft was used to demultiplex the data. The sequence reads were aligned to the 
human reference genome using Novoalign V2.07.13 from Novocraft (http://
www.novocraft.com). For Pt #5, hg18 downloaded from UCSC genome database was used 
and for Pt #8, b37 downloaded from GATK (Genome analysis toolkit) resources website 
was used for the reference genome. SAMtools v.0.1.1616 was used to sort and merge the 
data and Picard (http://picard.sourceforge.net/) was used to mark PCR duplicates. To correct 
the misalignments due to the presence of indels, local realignment was performed using 
RealignerTargetCreator and IndelRealigner of GATK17. Indel calls in dbSNP132 were used 
as known indel input. Then, GATK CountCovariates and TableRecalibration were used to 
recalibrate the originally reported quality score by using the position of the nucleotide within 
the read and the preceding and current nucleotide information. Finally, to call the single 
nucleotide variants (SNVs), the GATK UnifiedGenotyper was used to the realigned and re-
calibrated bam file while GATK IndelGenotyperV2 was used to call small insertion/
deletions (Indels). To generate a list of somatic variants for DP tumor, the difference in 
allele distribution was calculated using one-sided Fisher’s exact test using normal sample or 
the baseline sample. Variants with p-value<0.05 were included in the “somatic variant list”. 
Low coverage (<10X) SNVs and SNVs with more than one variant allele in normal tissue 
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and baseline melanoma were filtered out during the process. These somatic variants were 
further annotated with SeattleSeqSNPannotation (http://gvs.gs.washington.edu/
SeattleSeqAnnotation/). For DP-specific, non-synonymous SNVs that result in missense 
mutations, we assessed the level of amino acid conservation using PhyloP score (provided in 
UCSC genome database) where a score > 2 implies high conservation and the nature of 
amino substitution using Polyphen-2 analysis18.
CNV analysis was performed using an R package, ExomeCNV15. ExomeCNV uses the ratio 
of read depth between two samples at each capture interval. Here, the read depth data 
between baseline and DP melanomas were compared. Briefly, the read depth information 
was extracted through the PILEUP file generated from the BAM file after removing PCR 
duplicates using SAMtools. The average read depth at each capture interval was 
calculatedand the classify.eCNV module of ExomeCNV was run with the default parameters 
to calculate the copy number estimate for each interval. Subsequently, another R package 
commonly used to segment the copy number intervals, DNAcopy19, was called through 
ExomeCNV multi.CNV.analyze module with default parameters to do segmentation and 
sequential merging. The genomic regions with copy number 1 were called deletion and any 
regions with copy number >2 were called amplification. Circos20 was used to visualize the 
CNV data.
Protein detection
Western blots were probed with antibodies against p-ERK1/2 (T202/Y204), ERK1/2, C-
RAF, AKT (Ser473), AKT (Thr308), AKT (Cell Signalig Technologies; all at 1:1000), N-
RAS, B-RAF (Santa Cruz Biotechnology; both at 1:500), and tubulin (Sigma; 1:700). For B-
RAF immunohistochemistry, paraffin-embedded formalin-fixed tissue sections were 
antigen-retrieved, incubated with the primary antibody (Santa Cruz Biotechnology; 1:50) 
followed by HRP-conjugated secondary antibody (Envision System, DakoCytomation). 
Immunocomplexes were visualized using the DAB (3,3′-diaminobenzidine) peroxidase 
method and nuclei hematoxylin-counterstained.
Genomic DNA and RNA quantifications
For real-time quantitative PCR, total RNA was extracted and cDNA quantified by the 
iCycler iQ Real Time PCR Detection System (BioRad). Data were normalized to TUBULIN 
and GAPDH levels. Relative expression is calculated using the delta-Ct method. gDNAs 
were extracted using the FlexiGene DNA Kit (Qiagen) (Human Genomic DNA-Female, 
Promega). B-RAF relative copy number was determined by quantitative PCR (cycle 
conditions available upon request) using the MyiQ single color Real-Time PCR Detection 
System (Bio-Rad). Total DNA content was estimated by assaying β-globin for each sample, 
and 20 ng of gDNA was mixed with the SYBR Green QPCR Master Mix (Bio-Rad) and 2 
pmol/L of each primer. All primer sequences are provided in Supplementary Table S4.
Data processing
Statistical analyses were performed using InStat 3 Version 3.0b (GraphPad Software); 
graphical representations using DeltaGraph or Prism (Red Rock Software); and combination 
index calculation using CalcuSyn V2.1 (Biosoft). Calculations were made by CalcuSyn 
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software using the method of Chou and Taladay. Interpretation of CI values is summarized 
as follows: CI < 0.1 (very strong synergy); = 0.1–0.3 (strong synergy); = 0.3–0.7 (synergy); 
0.7–0.85 (moderate synergy); = 0.85–0.9 (slight synergy); = 0.90–1.10 (nearly additive); and 
= 1.10–1.20 (slight antagonism). The relevant correlated Log10 (CI) values are shown as 
follow: Log10 (CI 0.1) = −1; Log10 (CI 0.3) = −0.5228787452803376; Log10 (CI 0.7) = 
−0.1549019599857432, and Log10 (CI 0.85) = −0.07058107428570727.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Exome sequencing identifies V600EB-RAF amplification as a candidate mechanism for 
BRAFi resistance
(a) Copy number variations (CNVs) called from whole exome sequence data on two triads 
of gDNAs using ExomeCNV and chromosome 7 as visualized by Circos (outer ring, 
genomic coordinates (Mbp); centromere, red; inner ring, log ratio values between baseline 
and disease progression (DP) samples’ average read depth per each capture interval; scale of 
axis for Pt #5 −5 to 5 and for Pt #8 −2.5 to 2.5). Two patients whose melanoma responded to 
and then progressed on vemurafenib. The genomic region coded orange represents the 
location of B-RAF (chr7:140,424,943–140,524,564), which shows an average log ratio 
value of 1.14 (2.2 fold gain; Pt #5) and 3.8 (12.8 fold gain; Pt #8). (b) B-RAF 
immunohistochemistry on paired tissues derived from the same patients as in a (scale bar = 
50 μM) (c) Validation of V600EB-RAF copy number gain by gDNA qPCR (black and red by 
B-RAF primer set 1 and 2, respectively) and recurrence across distinct patients (positives 
highlighted in orange). PMN, peripheral mononuclear cells, and HDF, human dermal 
fibroblasts for diploid gDNAs. (d) B-RAF V600 mutant to WT ratio increases with disease 
progression or acquisition of B-RAFi resistance mediated by mutant B-RAF copy number 
gain. Chromatograms from Sanger sequencing for melanoma samples from patients who 
acquired B-RAFi resistance based on distinct molecular alterations: V600EB-RAF copy 
number gain, V600EB-RAF truncation, N-RAS mutation or RTK over-expression.
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Figure 2. V600EB-RAF levels modulate melanoma sensitivity to vemurafenib
(a, b) Western blot of V600EB-RAFV600E and p-ERK, tubulin is used as a loading control. 
Growth curve of did not alter the pERK level in the absence of vemurafenib/PLX4032 but 
conferred growth resistance to the parental line, M395 P when exposed to indicated 
concentrations of PLX4032 for 72 h (relative to DMSO-treated controls; mean ± SEM, n = 
5). Dashed line, 50% inhibition. (c, d) Transduction of shRNA to knockdown BRAFV600E in 
the drug-resistant sub-line, M395 R, did not alter the pERK level in the absence of PLX4032 
but restored growth sensitivity to PLX4032 (72 h; mean ± SEM, n = 5). (e) Increasing (in 
M395 P) or decreasing (in M395 R) BRAFV600E levels decreased or increased pERK 
sensitivity to PLX4032 (0, 0.1, 1, 10 μM) treatments for 1 h, respectively.
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Figure 3. Differential B-RAFi/MEKi sensitivities and C-RAF dependency
(a) Survival curves of B-RAFi acquired resistant sub-lines, with indicated mechanisms of 
resistance, to 72 h of B-RAFi (PLX4032) treatments, showcasing differential responses at 
the micro-molar drug range. Results are shown relative to DMSO-treated controls (mean ± 
SEM, n = 5; dashed line, 50% inhibition). (b) Survival curves of cell lines, engineered by 
viral transduction of M229 P to be B-RAFi resistant, to 72 h of B-RAFi (PLX4032) 
treatments, showcasing differential responses at the micro-molar drug range. Results are 
shown relative to DMSO-treated controls (mean ± SEM, n = 5). Expression of indicated 
viral expression constructs shown in Western blots. (c) Survival curves of B-RAFi acquired 
resistant sub-lines, with indicated mechanisms of resistance, to 72 h of MEKi (AZD6244) 
treatments, showcasing differential responses at the micro-molar drug range. Results are 
shown relative to DMSO-treated controls (mean ± SEM, n = 5). (d) Survival curves of cell 
lines (engineered by viral transduction of M229 P and M238 P to over-express V600EB-RAF 
rendering these parental cells resistant to B-RAFi) to 72 h of MEKi (AZD6244) treatments, 
showcasing differential responses at the micro-molar drug range. Pt55 R (double B-RAF and 
N-RAS mutant) is a short-term melanoma culture derived from a tumor which acquired 
PLX4032 (vemurafenib) resistance in a treated patient. Results are shown relative to 
DMSO-treated controls (mean ± SEM, n = 5). (e and f) Indicated cell lines were treated with 
constant ratios of PLX4032 and AZD6244 and survival measured after 72h. Relative 
synergies, expressed as log10 of CI values, are shown. (g) M249 (R4) and M395 R were 
seeded at single cell density and treated with indicated concentrations of PLX4032 and/or 
AZD6244. Inhibitors and media were replenished every two days, colonies visualized by 
crystal violet staining after 8 days of drug treatments, and quantified (% growth relative to 
cells treated with 1 μM PLX4032; representative of 2 experiments). Photographs 
representative of two independent experiments. (h) Survival curves of indicated cell lines 
after shScrambled or shC-RAF transduction (inset) and when treated with PLX4032 for 72 
h. (i) Clonogenic assays of cell lines in e with 14 days (M249 R4) or 18 days (M395 R) of 
PLX4032 treatment. Results are representative of 2 experiments.
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Figure 4. MAPK-reactivating mechanisms of acquired B-RAFi resistance and therapeutic 
implications
Distinct strategies to overcome acquired resistance driven by amplification of mutant B-RAF 
or mutations in N-RAS. Schematic of ERK-reactivating pathways (V600EB-RAF 
amplification indicated by stacked symbols, top; N-RAS mutation, bottom; mutant proteins 
in red and WT proteins in grey) and proposed strategies to restore B-RAFi sensitivity 
(increasing B-RAFi concentration or potency, top; switching B-RAFi to pan-RAFi, bottom). 
Alternatively, the combination of B-RAFi and MEKi are predicted to synergistically 
growth-inhibit melanomas with acquired resistance to B-RAFi monotherapy stemming from 
ERK reactivation.
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